CPT code 21029 designates surgical removal of a benign bone tumor by contouring or reshaping the affected bone and adjacent soft tissues. The procedure addresses deforming congenital or developmental bone abnormalities such as fibrous dysplasia and is a major invasive operation that may be performed in inpatient or ambulatory surgical settings. Nationally, the code matters because it captures complex reconstructive oncologic and congenital bone interventions that affect reimbursement, utilization tracking, and surgical quality measurement.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and what to expect from coverage and billing perspectives. The publication summarizes common reimbursement considerations, relevant benchmarks where available, and policy or coding updates that affect use of this code. It also provides guidance on typical clinical scenarios that prompt use of the code and notes where input data was not available.

This national-level brief is intended for billing specialists, surgical providers, and policy analysts seeking a clear synopsis of CPT code 21029, its clinical role, and payer scope.